Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth and product performance are overshadowed by declining margins and a significant net loss. Positive elements include strong recurring and reagent revenue growth, and new product success. However, the decline in profit margins and net loss, combined with unclear guidance on customer acquisition and demand, temper the overall sentiment. The Q&A highlights uncertainties in market growth and demand, further supporting a neutral outlook. Without market cap data, the reaction is expected to be muted, resulting in a neutral stock price prediction.
Key Financial Performance
Fourth Quarter Revenue $62.1 million, an 8% year-over-year increase. This growth was driven by stabilization and growth in the U.S., a turnaround in the EU, continued strength in APAC, and the expansion of recurring revenue businesses worldwide.
Full Year Revenue $201.5 million, a 1% year-over-year increase. The growth reflects improved trends and increased customer demand in the second half of the year, offsetting a 5% decline in the first half due to public policy issues affecting life sciences spending.
Recurring Revenue 34% of total revenue for 2025, growing 21% year-over-year. This growth was attributed to the expansion of the installed instrument base and increased usage of systems.
Reagent Revenue More than 20% growth in Q4 and over 25% for the full year 2025. This was driven by improved delivery times, a larger catalog of reagents, and new sales initiatives.
Instrument Unit Volume Growth 22% growth in 2025 compared to the prior year, accelerating to 26% growth in Q4. This was driven by the superior performance of Cytek's products and the success of the Aurora Evo system.
Service Revenue 25% growth in Q4 year-over-year, driven by the growth in the installed base and active usage of systems.
Gross Profit Margin (GAAP) 53% in Q4 2025, down from 59% in Q4 2024. The decline was due to higher service headcount and travel costs, higher material and tariff costs, and increased manufacturing overhead.
Adjusted Gross Profit Margin 55% in Q4 2025, down from 61% in Q4 2024. The decline was due to similar factors as the GAAP gross profit margin.
Net Loss (GAAP) $44.1 million in Q4 2025, compared to a net income of $9.6 million in Q4 2024. This included a $38.1 million valuation allowance against deferred tax assets.
Adjusted EBITDA $4.5 million in Q4 2025, down from $12.5 million in Q4 2024. The decline was due to higher operating expenses and lower gross profit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Aurora Evo System: Launched in May 2025, it has been successful, driving 21% unit growth in the combined Aurora category in Q4 2025 compared to Q4 2024.
Muse Micro System: Awarded the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year. It is a cost-effective flow cytometry solution with strong reception since its introduction.
Geographic Revenue Growth: EMEA and APAC posted double-digit year-over-year revenue increases in Q4 2025. U.S. revenue grew mid-single digits, driven by academic and government markets.
Recurring Revenue: Represented 34% of total revenue in 2025, growing 21% year-over-year, driven by increased instrument placements.
Manufacturing Facility in Singapore: Established in 2025, began generating revenue within 100 days, strengthening the region-for-region manufacturing strategy and supply chain resilience.
Reagent Business Improvements: Achieved over 20% growth in Q4 2025 due to best-in-class delivery times, a large catalog, and new sales strategies.
Digital Expansion: Cytek Cloud users grew to over 24,000 by year-end 2025, a 50% increase, enhancing product attractiveness and driving reagent revenue growth.
Stock Repurchase Program: Repurchased $15.1 million worth of stock in 2025, reducing outstanding shares to 128.6 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth Challenges: Revenue growth in 2025 was only 1% year-over-year, with significant declines in the first half of the year due to public policy issues affecting life sciences spending. This highlights vulnerability to external policy changes and weak demand in certain periods.
Geographic Revenue Disparities: While EMEA and APAC showed strong growth, the U.S. market experienced only mid-single-digit growth, and there were declines in instrument sales to biotech, pharma, and CRO customers. This indicates uneven performance across regions and customer segments.
Supply Chain and Tariff Costs: Higher materials and tariff costs, as well as duplicate costs from transitioning a production facility overseas, negatively impacted gross margins. This reflects ongoing supply chain and cost management challenges.
Operating Expense Increases: Operating expenses increased significantly, driven by higher legal expenses related to patent litigation, compensation, and software costs. This has contributed to a decline in profitability.
Biopharma Market Weakness: Revenue from biotech and pharma customers declined in Q4 2025, particularly in the U.S. and EMEA, following strong purchases in Q3. This highlights the volatility and dependency on biopharma customer demand.
Deferred Tax Asset Write-Off: A $38.1 million valuation allowance was recorded against deferred tax assets, reflecting uncertainty in realizing future tax benefits. This is a significant non-cash accounting loss that impacts financial results.
Gross Margin Decline: GAAP gross margin declined from 59% to 53% year-over-year in Q4 2025, driven by higher service costs, material costs, and manufacturing overhead. This indicates pressure on profitability.
R&D and Innovation Costs: R&D expenses decreased by 8% year-over-year, which could impact future innovation and competitiveness in the market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for 2026: Cytek projects full-year revenue for 2026 to be in the range of $205 million to $212 million, assuming constant currency exchange rates. This reflects an improved market environment in EMEA and the U.S., as well as continued strong growth in APAC instruments and global service and reagent businesses.
Recurring Revenue Growth: Recurring revenue, which represented 34% of total revenue in 2025, is expected to continue growing steadily as the installed instrument base expands, becoming an increasingly larger share of the business over time.
Market Trends and Stabilization: The company anticipates continued stabilization and growth in the U.S. and EMEA markets, with strong growth in APAC. The flow cytometry market is also beginning to show signs of stabilization, which is expected to support Cytek's performance.
Adjusted EBITDA: Cytek expects to maintain positive adjusted EBITDA in 2026, building on the positive adjusted EBITDA achieved in 2025.
Product and Service Growth: The company expects continued strong growth in its service and reagent businesses globally, driven by increased cumulative instrument placements and active usage of systems.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: During 2025, Cytek repurchased $15.1 million of its stock as part of its stock repurchase program. This repurchase involved approximately 3.3 million shares at a weighted average cost of $4.58 per share, leaving the company with 128.6 million shares outstanding as of December 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the underlying assumptions of the growth of the overall flow cytometry market, and are there geographic considerations for expansion?
A:The flow cytometry market has seen consistent double-digit growth in APAC, with mid-to-upper single-digit growth in the region. Europe has been the slowest market, while the U.S. falls in between. The market growth rates have been below high single-digit estimates globally in recent years but are expected to rebound.
Q:What drove the end-of-year growth acceleration, and how should budgets for 2026 be considered?
A:The growth acceleration was driven by a normalization in academic and government spending, catch-up disbursements from the NIH, deferred spending, and a currency benefit in EMEA. Academic and government sectors saw 5% growth for the year and 9% in the second half. The company assumes a continuation of this positive environment in its guidance for 2026.
Q:What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity, and what is expected for 2026?
A:The company does not break out these statistics but notes a combination of both new customer acquisitions and existing customers expanding capacity. Pharma companies tend to stick with their technology choices, and there are also conversions from competitor systems.
Q:What are the plans for commercial investments in 2026, and is the company comfortable with the size of its sales teams?
A:The company plans to continue investing in segments where it is weak to drive future revenue growth. Investments have also been made in the reagent sales force, and the commercial side will remain a focus for investment.
Q:What is the company's willingness to be flexible on pricing to drive instrument placements?
A:Pricing is market-driven, and the company has a competitive cost structure to adapt as needed.
Q:What is the magnitude of pent-up demand helping Q4, and how does it relate to steady-state growth?
A:The company saw a significant jump in academic and government revenues in Q4, which may partly be due to deferred spending from earlier in the year. However, it is difficult to estimate the exact magnitude of pent-up demand versus steady-state growth.
Q:What factors influenced the guidance range of 2% to 5% growth for 2026?
A:The guidance assumes strong growth in service and reagents, flat to modest growth in instruments, and includes contingencies for uncertainties. The high end of the range represents better performance in the instrument business and fewer contingencies.
Q:Review of Unclear Management Responses
A:The company avoided providing a direct answer regarding the mix of new customer acquisitions versus existing customers expanding capacity, stating that they do not break out these statistics. Additionally, the magnitude of pent-up demand in Q4 versus steady-state growth was not clearly estimated, as the company does not conduct customer-by-customer surveys to determine spending intentions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATM
Cloud
RD Research
adjustment item
allowance loss
allowance write
benefit amount
biotech pharma
case compensation
catalog reagent
compensation sale
cost write
demand government
digit percentage
expense reduction
facility margin
headcount
instrument demand
item loss
liability adjustment
life science
loss recording
manufacturing production
momentum
offering cost
recording valuation
reduction increase
return
settlement liability
strength
tax asset
valuation allowance
CTKB Transcript
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture: strong revenue growth and product performance are overshadowed by declining margins and a significant net loss. Positive elements include strong recurring and reagent revenue growth, and new product success. However, the decline in profit margins and net loss, combined with unclear guidance on customer acquisition and demand, temper the overall sentiment. The Q&A highlights uncertainties in market growth and demand, further supporting a neutral outlook. Without market cap data, the reaction is expected to be muted, resulting in a neutral stock price prediction.
Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals mixed signals. While there is strong growth potential in the reagent business and a strategic focus on innovation, the financial performance is concerning with a net loss and declining EBITDA. The Q&A highlights positive trends in Asia Pacific and biopharma, but challenges in EMEA and U.S. academic sectors persist. The cautious guidance for 2025 and stable U.S. performance balance the negatives, leading to a neutral sentiment rating.
Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-10
Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call reveals mixed signals. While there are positive aspects such as improved net loss, increased service revenue, and strategic product launches, there are concerns about declining revenue, lower gross margins, and uncertainties in academic funding. The Q&A highlights management's cautious optimism, with no clear guidance on macroeconomic impacts. Despite some positive product developments, the overall sentiment remains neutral due to the lack of strong financial performance and clear guidance. The market's reaction is likely to be muted, resulting in a neutral stock price movement.
CTKB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
